Board Comprised of Leading Dermatology Experts and Lifescience Investors
WESTLAKE VILLAGE, CA / ACCESSWIRE / April 30, 2019 / Arcutis, Inc., a privately held immuno-dermatology drug development company addressing significant unmet needs in dermatology, today announced its Board of Directors. The Board is led by Executive Chairman Bhaskar
Chaudhuri, Ph.D., Operating Partner at Frazier Healthcare and previously the CEO of Dow Pharmaceutical Sciences and President of Valeant Pharmaceuticals.
Other members of the Arcutis’ Board of Directors include:
Dan Estes, Ph.D., Partner on the Frazier Healthcare Life Sciences team
Patrick Heron, Managing General Partner of the Frazier Healthcare Life Sciences team
Jonathan Silverstein, J.D., Managing Partner and Co-Head of Global Private Equity at OrbiMed
Charles Stiefel, J.D., former Chairman and CEO of Stiefel Laboratories, Inc.
Ricky Sun, Ph.D., Partner, Bain Capital Life Sciences
Frank Watanabe, M.A., President and CEO, Arcutis, Inc.
Dr. Chaudhuri commented: “We are honored to have such a distinguished group of individuals supporting Arcutis. The Board’s combined experience in dermatological drug development, biopharmaceutical industry investment and corporate leadership has been invaluable in guiding Arcutis to this point, and we look forward to their strategic input as we continue to advance our pipeline of novel compounds currently in clinical development for multiple dermatology indications.”
Arcutis’ combination of vision, opportunity to address unmet medical needs, experienced management and strategic approach has attracted support from leading investors in the life sciences sector, including: Frazier Healthcare Partners,
Bain
Capital Life Sciences, OrbiMed, RA Capital
Management, Hillhouse Capital Group, and Rainbow Group Capital Management. Arcutis has successfully completed Series A and Series B financings, the proceeds of which are funding its clinical development programs and corporate operations.
About Arcutis
Arcutis is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs that address significant unmet medical needs in immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop best-in-class molecules against biologically validated targets, leveraging our industry-leading development expertise to bring to market novel dermatology treatments in less time, at lower cost and with lower risk than other approaches. Arcutis is currently developing two novel compounds (ARQ-151 and ARQ-250) for multiple indications including, psoriasis, atopic dermatitis, and eczema. Find more information at www.arcutis.com. Arcutis – Bioscience, applied to the skin.
Contact:
T. Frank Watanabe
Chief Executive Officer
Investors and Media:
Derek Cole
720.785.4497
SOURCE: Arcutis, Inc.
View source version on accesswire.com:
https://www.accesswire.com/543472/Arcutis-Inc-Announces-Board-of-Directors
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…
Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…
AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…
NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…